- Home
- ILPT vs ANNX Comparison
ILPT vs ANNX Comparison
Compare ILPT & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILPT
- ANNX
- Stock Information
- Founded
- ILPT 2017
- ANNX 2011
- Country
- ILPT United States
- ANNX United States
- Employees
- ILPT N/A
- ANNX N/A
- Industry
- ILPT Real Estate Investment Trusts
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- ILPT Real Estate
- ANNX Health Care
- Exchange
- ILPT Nasdaq
- ANNX Nasdaq
- Market Cap
- ILPT 217.6M
- ANNX 252.3M
- IPO Year
- ILPT 2018
- ANNX 2020
- Fundamental
- Price
- ILPT $4.75
- ANNX $2.38
- Analyst Decision
- ILPT Buy
- ANNX Strong Buy
- Analyst Count
- ILPT 2
- ANNX 4
- Target Price
- ILPT $10.00
- ANNX $12.50
- AVG Volume (30 Days)
- ILPT 433.3K
- ANNX 1.4M
- Earning Date
- ILPT 07-29-2025
- ANNX 08-11-2025
- Dividend Yield
- ILPT 0.84%
- ANNX N/A
- EPS Growth
- ILPT N/A
- ANNX N/A
- EPS
- ILPT N/A
- ANNX N/A
- Revenue
- ILPT $441,992,000.00
- ANNX N/A
- Revenue This Year
- ILPT $3.09
- ANNX N/A
- Revenue Next Year
- ILPT $1.79
- ANNX N/A
- P/E Ratio
- ILPT N/A
- ANNX N/A
- Revenue Growth
- ILPT 0.61
- ANNX N/A
- 52 Week Low
- ILPT $2.45
- ANNX $1.29
- 52 Week High
- ILPT $5.45
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- ILPT 79.82
- ANNX 54.28
- Support Level
- ILPT $3.35
- ANNX $2.26
- Resistance Level
- ILPT $4.83
- ANNX $2.81
- Average True Range (ATR)
- ILPT 0.24
- ANNX 0.21
- MACD
- ILPT 0.15
- ANNX -0.02
- Stochastic Oscillator
- ILPT 96.36
- ANNX 45.68
About ILPT Industrial Logistics Properties Trust of Beneficial Interest
Industrial Logistics Properties Trust is a real estate investment trust. It owns and leases industrial and logistics properties throughout the United States. The company's investment portfolio includes industrial lands in Hawaii and industrial and logistics properties in other states. Rental revenue is earned from Hawaii Properties and Mainland Properties.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.